Claudio Gobbi, MD
Ospedale Regionale di Lugano, Neurocentro della Svizzera italiana, Centro Sclerosi multipla · Ospedale Regionale di Lugano - Civico · Neurocenter of Southern Switzerland
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Claudio Gobbi, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:07 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04640818 · Safety and Efficacy of Cladribine Therapy After Anti CD20 TherapyClaudio Gobbi · unknown · Multiple Sclerosis · principal investigator
- N/ANCT02082002 · Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - TicinoClaudio Gobbi · completed · Multiple Sclerosis · principal investigator
- Ph4NCT01701856 · Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple SclerosisClaudio Gobbi · terminated · Relapsing-remitting Multiple Sclerosis · principal investigator
- Ph4NCT01411514 · Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple SclerosisClaudio Gobbi · terminated · Multiple Sclerosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.